Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-282

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)

Chemical structure of Losartan Potassium, showing its molecular components including aromatic rings, chlorine, hydroxyl group, and potassium ion, consistent with the generic ingredient Losartan Potassium in the 25 mg oral film-coated tablet.*

FDA Label Image

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months between Atenolol (dotted line) and Losartan potassium (solid line). The graph shows a lower percentage for Losartan potassium, with an adjusted risk reduction of 13% (p=0.021). The x-axis represents study months, and the y-axis represents the percentage of patients with the primary endpoint.*

FDA Label Image

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol (dashed line) and Losartan potassium (solid line). The graph shows a lower stroke incidence for Losartan potassium with an adjusted risk reduction of 25% (p=0.001) across approximately 66 months.*

FDA Label Image

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)

A forest plot chart comparing event rates and hazard ratios between Losartan Potassium and Atenolol. It displays data split by overall results and subgroups including age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The left panel shows primary composite events and the right panel shows stroke (fatal/non-fatal) events, with hazard ratios and 95% confidence intervals favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)

A line graph comparing the percentage of patients with an event over 48 months between those treated with Losartan potassium and placebo. The graph shows a continuous increase over time, with a noted risk reduction of 16.1% and a p-value of 0.022, indicating statistical analysis. Losartan potassium data is represented by a solid line, placebo by a dotted line.*

FDA Label Image

72789282 Label (72789282)

Label for Losartan Potassium USP 25 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The label shows the product name, strength, quantity of 30 tablets, NDC 72789-282-30, and manufacturer information from Oklahoma City, OK. It includes dosage instructions space, warnings to keep out of reach of children, and expiration date 12/2023, lot J22C10.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.